secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001711279-23-000031
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech Q1 net loss $45.3M, cash $355.5M, PDUFA date May 19 for B-VEC
-----------------------------------------------------------------------------

- Net loss of $45.3M ($1.76 per share) vs $50.0M loss ($1.99) in Q1 2022.
- Cash, equivalents & investments $355.5M at March 31, 2023.
- R&D expense $12.3M (up from $9.3M); G&A expense $24.0M (up from $15.9M).
- PDUFA date for B-VEC Biologics License Application is May 19, 2023; labeling discussions started in April.
- Topical B-VEC in eye under compassionate use showed vision improvement from hand motion to 20/40 at 7 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000031/0001711279-23-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000031/krys-20230508.htm
  HTML page:      https://secwatch.observer/filing/0001711279-23-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer